SEMINAR NASIONAL KEFARMASIAN 2026

Main ideas / lessons conveyed

• Purpose of the seminar: Highlighted the urgent global and national health challenge of antibiotic resistance and the role of pharmacists in preventing and overcoming it.
• Why antibiotic resistance happens:
  • Resistance occurs when microorganisms survive at therapeutic antibiotic doses, reducing antibiotic effectiveness, increasing disease spread, and leading to severe outcomes.
  • Resistance is worsened by misuse and inappropriate use of antibiotics, such as:
    • wrong indication
    • wrong drug
    • wrong dose/route/duration
    • failure to reassess
  • Antibiotic exposure shapes resistance over time, affecting not only individuals but also the environment and community transmission.
• Pharmacists’ responsibilities:
  • Pharmacists are not only dispensers; they educate and participate in stewardship teams.
  • They support rational drug use, monitor therapy, prevent drug interactions and errors, and help ensure appropriate antibiotic selection and duration.
• National strategy / framework for tackling AMR:
  • Includes awareness/education, preventive measures, access to health services, timely and accurate diagnosis, and proper treatment with guaranteed quality.
  • Emphasizes antimicrobial stewardship and the need for multidisciplinary collaboration.
• Hospital program structures:
  • Hospitals use antibiotic stewardship structures such as ASP / antimicrobial stewardship programs and PPRA-type antibiotic control committee concepts (as described).
  • Surveillance tracks antibiotic use patterns (qualitative/quantitative) to guide interventions.
• Global urgency and impact:
  • AMR leads to higher mortality, harder-to-treat infections, more complications, and major economic losses.
  • Indonesia-specific risks were mentioned, including:
    • higher mortality risks in certain resistant TB contexts
    • rising resistance trends (e.g., E. coli/pneumonia relationships)
• “Smart antibiotic use” principles (education + reassessment loop):
  • Proper antibiotic use is a continuous “journey” of decisions, not a one-time prescription.

---

Methodology / instruction-like content

A) Event agenda and procedural steps (seminar flow)

• Opening:
  • Read Basmalah (“Bismillahirrahmanirrahim”)
  • Sing Indonesia Raya
  • Sing the Poltekes Hymn and Mars
• Sponsor screening
• Display campus profiles
• Read procedural rules
• Group photo session
• Welcome speeches
• Presentation of material, followed by:
  • Q&A session
  • Quiz session(s)
  • Final closing

B) Rules of procedure for seminar participants (virtual/Zoom)

• Prepare:
  • Ensure stable internet connection and a working device
• Identity & conduct:
  • Use the required name format as your Zoom identity
  • Dress neatly and politely
  • Use the prepared virtual background
  • Complete required links: attendance, opening, closing
• During the event:
  • Keep camera on during the seminar (activate it if not already)
  • Turn off microphone unless the MC/moderator requests otherwise
  • Maintain smooth participation until the event ends
• Group photo:
  • Turn camera on when instructed and follow the countdown

C) Antibiotic stewardship / “smart antibiotic use” methodology (content instructions)

Smart antibiotic use is described as a loop combining “right” elements and reassessment.

• Right Indication
  • Give antibiotics only when there is evidence/suspicion of bacterial infection
  • Fever alone is not always bacterial—reassess diagnosis
• Right Drug
  • Select an antibiotic appropriate to the likely/confirmed pathogen and local policies
  • Avoid inappropriate choices (e.g., use a narrower spectrum when appropriate)
• Right Dose
  • Dose must match patient factors (kidney/liver function, pregnancy status, age/frailty, etc.)
  • Under/overdosing increases risk of failure, toxicity, and resistance
• Right Route
  • Use the correct route (e.g., consider switching from IV to oral when appropriate)
• Right Duration
  • Provide the correct length of therapy; avoid unnecessary excess
• Right Timing / Interval
  • Administer at the correct intervals (timing deviations can contribute to failure/resistance)
• Reassess (core loop step)
  • Reassess if the patient improves, worsens, or stagnates
  • Use culture results when available to shift from empirical to definitive therapy
  • If improved and criteria are met, adjust (possibly step down) and eventually stop antibiotics

D) Antibiotic therapy decision approach (empirical → definitive)

• Diagnose infection using appropriate indicators/tools.
• Empirical therapy
  • Used before culture results are available, guided by clinical signs
  • Emphasized: empirical antibiotics can fail or drive resistance if incorrect
• Definitive therapy
  • After culture/susceptibility results, switch to the targeted antibiotic regimen

E) Prophylactic antibiotic principles (as described)

• Prophylactic antibiotics are given in relation to surgical procedures (before/around surgery).
• Selection depends on:
  • procedure type
  • patient factors (including allergies)
• Administration windows include timing “before surgery” and repeated dosing rules depending on procedure duration/conditions.
• Example themes:
  • prefer correct generation/spectrum for prophylaxis when appropriate
  • adjust for allergies and the expected contamination level

F) Surveillance and evaluation (PPRA/AMR control concepts)

• Qualitative vs quantitative surveillance:
  • Quantitative: calculate using antibiotic use values and denominators (e.g., hospital patient stay/number of inpatients)
  • Qualitative: assess appropriateness to identify issues (correct regimen, spectrum, dose, indication, etc.)
• Interventions are based on surveillance priorities:
  • start with highest-importance areas (e.g., surgeries), then expand to other settings
• Evaluation outcomes:
  • track compliance and reasons for non-compliance
  • use findings to update and improve future stewardship policies

---

Speakers / sources featured (identified)

1. Pharmacist Hanita Kristianari, SF, MF — Head of the D3 Pharmacy Study Program (opening remarks)
2. Berlia Nur Azahra — MC
3. Ms. Berlian — MC referenced during reminders/flow (same role as Berlia Nur Azahra)
4. Mr. Dr. Ana Samat Hidayat, SKM, MKes — Director mentioned; welcomed in official remarks
5. Natas Linta Widowo — Chair of the committee (welcome remarks)
6. Pharmacist Idulhat(d) Tilalah, SFAM, M.Ph — Moderator (includes CV reading)
7. Pharmacist Nadya Saptarina — First resource person; Master of Pharmacy Certified Trainer
8. Pharmacist Hanifah Iksan Septor Rini — Second resource person; works at UGM Academic Hospital (Master’s-level presenter)
9. Ms. Ratih Purwanti, S.Si., M.S. — Assistant Director 1 (addressed in speeches)
10. Ms. Harpeni Siswati Budi, SPSI, MPH — Assistant Director 2 (addressed in speeches)
11. Pharmacist Darog Hernawan, M.Sc. — Assistant Director 3 (addressed in speeches)
12. Francis Nubanara — participant asking a question in Q&A
13. Victoria Nilanem — participant asking a question in Q&A
14. Dita Linia Putri — participant asking a question in Q&A
15. Hikmah — participant answering a quiz question
16. Maria Donda — quiz participant answerer
17. Eva Dian Lestari — quiz participant answerer
18. Famelia — quiz participant answerer
19. Andin — quiz participant from East Nusa Tenggara (likely “Andini” per transcript)
20. MC “Indrahatul Bilala, SFAM, M.Ph” — moderator role handed back at the end

Sponsors mentioned (credited in opening)

• Sehat 42 drug figure
• Sumber Sehat Pharmacy
• Hu Dental Care Clinic
• W Almade Photocopy
• Engels Pharmacy

Organizations / program concepts referenced (sources in content)

• WHO (World Health Organization) antibiotic surveillance/usage calculation and framework references
• National AMR strategy pillars (Indonesia Ministry of Health mentioned)
• ASP (Antimicrobial Stewardship Program concept)
• PPRA / antibiotic control committee concept (as described in the talk)
• RESISTANCE/AMR concepts and study examples (multiple international studies referenced)